EFFECTIVITY ANALYSIS OF NEUROPROTECTOR (VITAMIN B COMPLEX AND MECOBALAMIN) AS NEUROPATHIC PAIN SUPPORTIVE THERAPY IN ELDERLY WITH TYPE 2 DIABETES MELLITUS

MADE KRISNA  ADI JAYA; NI MADE OKA  DWICANDRA

doi:10.22159/ajpcr.2017.v10i12.21845

Authors

MADE KRISNA ADI JAYA Department of Clinical Pharmacy, Health Sciences Institute Medika Persada Bali, Denpasar, Bali, Indonesia.
NI MADE OKA DWICANDRA Department of Clinical Pharmacy, Health Sciences Institute Medika Persada Bali, Denpasar, Bali, Indonesia.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i12.21845

Keywords:

Effectivity, Vitamin B complex, Mecobalamin, Neuropathic pain, Elderly

Abstract

Objective: Neuroprotector (Vitamin B complex or mecobalamin)is often used as a supportive neuropathic pain therapy. The effectiveness of this drug remains controversial, especially in geriatrics with Type 2 diabetic neuropathy pains. The aim of this study was to compare the diabetes neuropathic pain reduction in elderly with and without neuroprotective supplementation.

Method: The study was conducted by prospective cohort design. 132 agings were observed during 4 weeks at Neurology Polyclinic, Sanglah Public Hospital, Denpasar, Bali-Indonesia. Individuals undergoing the first-line neuropathic pain therapy who received neuroprotector supplementation were included in the exposure group (66 individuals), while those not receiving neuroprotective supplementations were included in the nonexposure group (66 individuals). The pain scores were measured by numeric rating scales instruments. The measured outcome was a decrease in diabetic neuropathic pain scores.

Result: Both groups showed reduce on pain scores statistically different compared to baseline pain score (p<0.05). The comparison head-to-head on neuroprotector supplementation group showed significantly greater to reduce the pain score compared to nonexposure group (p<0.05). The relative risk of pain score reduction more than 2 units was 1.37 (confidence interval [CI]95%: 1.05-1.80)and the number need to treat was 5 (CI 95%: 3-28) compared to nonexposure group.

Conclusion: Individuals who are undergoing the first-line neuropathic pain therapy and getting Vitamin B complex or mecobalamin supplementation had decreased pain intensity better than without supplementation therapy.

Downloads

Download data is not yet available.

Author Biographies

MADE KRISNA ADI JAYA, Department of Clinical Pharmacy, Health Sciences Institute Medika Persada Bali, Denpasar, Bali, Indonesia.

Clinical Pharmacy Department

NI MADE OKA DWICANDRA, Department of Clinical Pharmacy, Health Sciences Institute Medika Persada Bali, Denpasar, Bali, Indonesia.

Clinical Pharmacy Department

References

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53.

Rasolabadi M, Khaledi S, Ardalan M, Kalhor MM, Penjvini S, Gharib A. Diabetes research in Iran: A scientometric analysis of publications output. Acta Inform Med 2015;23(3):160-4.

Han C, Whiting D, Guariguata L, Brown A, Dahlquist G, Dodd S, et al. IDF Diabetes Atlas. Int Diabet Fed 2013;???:14-25.

Tesfeye S. Epidemiologi and etiology of diabetic pheripheral neuropathies. Adv Stud Med 2004;4:1014-21.

Keban SA, Najuah N, Abdillah S. The role of pharmacists in evaluating and intervening the patients with diabetic neuropathy. Asian J Pharm Clin Res 2017;10:127-31.

Moradi M, Mousavi S. Drug use evaluation of diabetes mellitus in non-hospitalized patients. Int J Pharm Pharm Sci 2016;8:337-41.

Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis 2015;6(1):15-28.

Wagle L, Thomas AA, Shrestha S. Drug utilisation study of stroke and other patients admitted to general ward of neurology unit at quaternary care private hospital. Int J Curr Pharm Res 2017;9:23-8.

Jayabalan B, Low LL. Vitamin B supplementation for diabetic peripheral neuropathy. Singapore Med J 2016;57(2):55-9.

Dominguez JC. A prospective open label 24-week trial of methylcobalamin in the treatment of diabetic polyneuropathy. J Diabet Mel 2012;02:408-12.

Vasudevan D, Naik MM, Mukaddam QI. Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in Type 2 diabetes associated impaired peripheral neuropathic condition. Ann Indian Acad Neurol 2014;17:19-24.

Sun Y, Lai MS, Lu CJ. Effectiveness of vitamin B12 on diabetic neuropathy: Systematic review of clinical controlled trials. Acta Neurol Taiwan 2005;14(2):48-54.

Thakur S, Srivastava N. An update on neuropathic pain models. Int J Pharm Pharm Sci 2016;8:11-6.

Weir DG, Scott JM. The biochemical basis of the neuropathy in cobalamin deficiency. Baillieres Clin Haematol 1995;8(3):479-97.

Metz J. Pathogenesis of cobalamin neuropathy: Deficiency of nervous system S-adenosylmethionine? Nutr Rev 1993;51(1):12-5.

Arora H, Srivastava N, Bala K. Prevalence of vitamin D/B12 deficiency among urban populations complaining pain of lower limb and generalize weakness. Asian J Pharm Clin Res 2016;9:261-3.